![Loading...](https://link.springer.com/static/c4a417b97a76cc2980e3c25e2271af3129e08bbe/images/pdf-preview/spacer.gif)
-
Article
Open AccessThe lived experience of juvenile idiopathic arthritis in young people receiving etanercept
This study explores young people’s daily experiences of living with Juvenile Idiopathic Arthritis (JIA) and their thoughts, beliefs and feelings related to the biological drug Etanercept, prescribed as part of...
-
Article
Open AccessPReS-FINAL-2130-A: Effectiveness of intravenous cyclophosphamide in severe or refractory juvenile dermatomyositis - a national cohort study UK and Ireland
-
Article
Open AccessPReS-FINAL-1009: Antioxidant superoxide dismutase activity is paradoxically normal in juvenile systemic lupus erythematosus
-
Article
Open AccessPReS-FINAL-1011: Can repeated T cell receptor stimulation lead to epigenetic reprogramming of the treg-specific demethylated region in human conventional T cells?
-
Article
Open AccessPReS-FINAL-1021: Further characterization of CD161+ regulatory t cells in health and disease
-
Article
Open AccessPReS-FINAL-1002: Dissecting the dissociation of foxp3 and cd25 expression on cd4+ t cells in synovial fluid identifies three distinct subpopulations of human t regulatory cells present at the chronically inflamed site
-
Article
Open AccessPReS-FINAL-1017: Antioxidant superoxide dismutase activity is elevated in jia but not associated with disease activity
-
Article
Open AccessPReS-FINAL-1001: Lymphocytes from the inflamed joint of juvenile idiopathic arthritis patients express reduced levels of cd73 and have a functional defect in adenosine production
-
Article
Open AccessPReS-FINAL-2130: Antibodies to MDA5 correlate with a distinct phenotype in children with juvenile dermatomyositis, including higher risk of lung involvement and ulcerative skin disease
-
Article
Open AccessPReS-FINAL-2135: Analysis of the HLA region in a large cohort of juvenile idiopathic arthritis cases identifies independent effects at HLA-DRB1
-
Article
Open AccessCan inflammatory markers predict response to methotrexate in JIA? Results from the CHARM study
-
Article
Open AccessComparison of data from the juvenile dermatomyositis national (UK & Ireland) cohort biomarker study and repository for idiopathic inflammatory myopathies with a survey of current practice throughout the UK and Ireland
-
Article
Open AccessCharacterising inflammatory markers in two childhood autoimmune diseases (JIA and JDM) pre and post methotrexate
-
Article
Open AccessMyeloid cells which secrete S100 proteins in juvenile dermatomyositis may contribute to disease activity
-
Article
Open Access15.3 Agreement between parent and adolescent assessment of disability, pain and well-being: results from the Childhood Arthritis Prospective Study (CAPS)
-
Article
Open AccessAssociation between IL2RA and juvenile idiopathic arthritis (JIA) disease severity at first presentation to paediatric rheumatology: results from the Childhood Arthritis Prospective Study (CAPS)
-
Article
Open AccessAn in-depth analysis of young people's experience of their juvenile idiopathic arthritis (JIA) once receiving Etanercept
-
Article
Open Access14.4 Oligoarticular Juvenile Idiopathic Arthritis (JIA): can extension be predicted?
-
Article
Open AccessInvestigating which variables from the core outcome variables in juvenile idiopathic arthritis (JIA) are the best predictors of classification as a responder to treatment with methotrexate (MTX)
-
Article
Open Access7.2 Interleukin-17 (IL-17) secreting cells in synovial fluid express the "Th17" master transcription factor RORC and their numbers correlate with CCL20 levels within the joint